Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM4 | Q14833 | 2/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.37 |
| ▸ | AR | P10275 | 9/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.35 |
| ▸ | FSCN1 | Q16658 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | KCNQ3 | O43525 | 1/20 | 0.34 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.34 |
| ▸ | KCNE1 | P15382 | 1/20 | 0.34 |
| ▸ | KCNQ1 | P51787 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21497983 | 0.85 | GRM4 (0.42) | GRM4KCNH2ARALDH1A1L3MBTL1 | |
| SCHEMBL21428284 | 0.85 | GRM4 (0.43) | GRM4KCNH2ARALDH1A1L3MBTL1 | |
| SCHEMBL16416898 | 0.84 | GRM4 (0.45) | GRM4KCNH2ARALDH1A1L3MBTL1 | |
| SCHEMBL19881915 | 0.82 | GRM4 (0.49) | GRM4KCNH2ALDH1A1L3MBTL1RXFP1 | |
| SCHEMBL21497984 | 0.80 | GRM4 (0.40) | GRM4KCNH2ARRXFP1FSCN1 | |
| SCHEMBL16421451 | 0.80 | GRM4 (0.43) | GRM4KCNH2ARALDH1A1L3MBTL1 | |
| SCHEMBL32682229 | 0.79 | GRM4 (0.44) | GRM4KCNH2ALDH1A1L3MBTL1RXFP1 | |
| SCHEMBL22511266 | 0.79 | GRM4 (0.44) | GRM4KCNH2ALDH1A1L3MBTL1RXFP1 | |
| SCHEMBL17838294 | 0.77 | SLC10A1 (0.44) | GRM4KCNH2ARALDH1A1L3MBTL1 | |
| SCHEMBL17838260 | 0.77 | SLC10A1 (0.44) | GRM4KCNH2ARALDH1A1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10450270-B2 | Glyoxamide substituted pyrrolamide derivatives and the use thereof as medicaments for the treatment of hepatitis B | JANSSEN SCIENCES IRELAND UC (IE) | 2019-10-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10450270-B2 | Glyoxamide substituted pyrrolamide derivatives and the use thereof as medicaments for the treatment of hepatitis B | GRHPR, AGXT, GLS2 | GRM4 2037/4885KCNH2 4441/4885AR 3664/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.